BSE · 531762
Unjha Formulations Ltd.
Revenue & net profit by period
Bars = revenue (₹ Cr) · line = net profit (₹ Cr). Straight from disclosed results.
Latest period: revenue ₹16 Cr with net profit ₹1 Cr — a 4.48% net margin, versus 2.92% the period before.
Shareholding
As of 2026-09-30
- Promoter36.92%
- Public63.08%
4,443 shareholders on record
Promoter holding trend
Each disclosed period, oldest to newest
52-week position
Where the current price sits in its yearly band
The band spans 2.08× from low to high.
Risk flags
Derived from disclosed data
- Under exchange surveillance — ESM · ESM 1. Trading may carry price bands, periodic call auction or higher margins.
Peer comparison
Pharmaceuticals - Indian - Formulations · ranked #41 of 51 by market cap · medians across 43 industry peers
| Company | Mkt cap | P/E | P/B | ROE | Margin |
|---|---|---|---|---|---|
| Torrent Pharmaceuticals Limited | ₹1,77,632 Cr | 81.81 | 9.65 | 11.42% | 12.27% |
| Gland Pharma Limited | ₹55,016 Cr | 43.91 | 5.15 | 11.57% | 17.48% |
| Ajanta Pharma Limited | ₹41,037 Cr | 32.5 | 8.45 | 25.99% | 20.31% |
| Rubicon Research Limited | ₹27,764 Cr | 85.48 | 19.63 | 22.94% | 15.47% |
| Shilpa Medicare Ltd. | ₹19,392 Cr | 60.64 | 7.04 | 12.05% | 18.05% |
| Caplin Point Laboratories Ltd. | ₹18,157 Cr | 26.35 | 4.65 | 17.66% | 28.91% |
| Eris Lifesciences Limited | ₹18,136 Cr | 24.23 | 4.38 | 17.07% | 21.36% |
| Marksans Pharma Limited | ₹14,435 Cr | 25.79 | 4.33 | 16.8% | 16.51% |
| Bliss GVS Pharma Ltd. | ₹7,161 Cr | 44.02 | 5.55 | 12.49% | 15.01% |
| Senores Pharmaceuticals Limited | ₹5,409 Cr | 40.53 | 5.39 | 13.31% | 18.57% |
| Unjha Formulations Ltd.(this company) | ₹13 Cr | 77.7 | 2.86 | 3.63% | 1.11% |
AI analysis
AI-generated · google/gemini-2.5-flashUnjha Formulations Ltd. (531762) has a market capitalization of Rs 11 Cr. The company's EPS stands at 1.57, with a Book Value of 8.57. Its Return on Equity (ROE) is 18.34% and Return on Capital Employed (ROCE) is 25.02%. The debt-to-equity ratio is 0, indicating no debt.
Positives
- +The company has no debt, as indicated by a debt-to-equity ratio of 0.
- +Promoter pledging is 0% as of June 2026, indicating no shares are pledged.
- +The profit margin is 455.42%, which is high.
- +Return on Capital Employed (ROCE) is 25.02%, while Return on Equity (ROE) is 18.34%.
Negatives
- −The company's revenue declined to Rs 13.98 Cr in Mar 2025 from Rs 18.51 Cr in Mar 2024.
- −The company reported a negative net profit for March 2026 of Rs -0.74 Cr and in March 2025 of Rs -0.41 Cr.
- −No DII or FII shareholding was reported for the period ending June 2026.
- −Quarterly EPS figures were not provided in the available data.
- −Quarterly revenue in Mar 2026 was Rs 3.33 Cr, a decrease from Rs 4.44 Cr in Dec 2025.
Financial performance
Unjha Formulations Ltd. reported revenue of Rs 13.98 Cr in Mar 2025. This compares to a revenue of Rs 18.51 Cr in Mar 2024. Net profit for Mar 2025 was Rs 0.41 Cr, which followed a net profit of Rs 0.28 Cr in Mar 2024. The EPS in Mar 2025 was 0.91, an increase from 0.62 in Mar 2024.
Profitability & returns
The company's profit margin is 455.42%. Return on Equity (ROE) is 18.34% and Return on Capital Employed (ROCE) is 25.02%. In the latest annual report for Mar 2025, EBITDA was Rs 0.53 Cr, and net profit was Rs 0.41 Cr.
Balance sheet
Unjha Formulations Ltd. has a debt-to-equity ratio of 0, indicating no debt. The book value per share is Rs 8.57. The absence of long-term debt could suggest a conservative financial approach or limited need for external financing.
Ownership & pledges
Public shareholding stands at 63.075%. There are no shares pledged by the promoters. The company has 4223 shareholders as of June 2026. No DII or FII holdings were reported.
Data as of — price: 2026-11-14 · financials: Mar 26 · shareholding: Sep 26. Figures are restated only when the company files again, so a period shown here is the most recent one on record — not necessarily the current quarter.
How this is produced: every figure above is computed from exchange filings and financial data mirrored by IPO Plus — no figure is generated or estimated. This is a factual summary for information and education only. It is not investment advice, not a recommendation to buy, sell or hold any security, and contains no price targets. Verify against the company's filings and the exchanges before any decision.